All lobbying filings

TULIPIFERA STRATEGIES

Lobbying for TREATMENT ADVOCACY CENTER · Advocacy, education, and research related to eliminating barriers to the treatment of SMI.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Virginia · House · Senate · $10,000.00 income · posted May 1, 2026

Official filing document

Lobbying activity 1

Health Issues

Medicaid IMD Exclusion. The IMD Exclusion, within Sec. 1905(a) of the Social Security Act, generally excludes federal fund participation for treatment provided in an inpatient psychiatric facility. Medicare lifetime limit on impatient psychiatric care. Medicare generally imposes a 190 day lifetime limit on treatment provided in an inpatient psychiatric facility.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.